Search results
Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine
Zacks via Yahoo Finance· 13 hours agoNovavax (NVAX) seeks FDA???s approval to update its COVID-19 vaccine for the 2024-2025 fall season...
Novavax seeks FDA approval for updated Covid-19 vaccine
Pharmaceutical Technology via Yahoo Finance· 20 hours ago"Novavax seeks FDA approval for updated Covid-19 vaccine" was originally created and published ...
Novavax applies for FDA nod for its updated COVID vaccine
Center for Infectious Disease Research and Policy· 5 hours agoThe company said it will have the vaccine ready to distribute in mid July as prefilled syringes, pending approval and recommendations.
New COVID-19 strain KP.3 circulating in US. What is the situation in Riverside County?
The Desert Sun· 3 days agoA new COVID-19 variant called KP.3 is on the rise in the United States and has been detected in...
KP.3 is the dominant COVID-19 variant in the US: Latest on test positivity, deaths, symptoms
USA Today· 4 days agoCases of the latest COVID-19 variant, also known as KP.3, are on the rise in the United States....
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
Zacks via Yahoo Finance· 3 days agoData from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved...
3 Vaccine Stocks to Buy as the FDA Cracks Down on New Variants
InvestorPlace via Yahoo Finance· 7 days agoOn Friday, the U.S. Federal Drug Administration (FDA) okayed the launch of updated vaccines as part...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 5 days agoAnd Moderna stock surged more than 9% on Dec. 19, the day it released the news. Moderna also...
Moderna director Afeyan sells over $30 million in company stock By Investing.com
Investing.com· 6 days agoModerna , Inc. (NASDAQ:MRNA) Director Noubar Afeyan has sold a significant number of company shares,...
Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing
BioPharma Dive via Yahoo Finance· 4 days agoThe Japanese pharma paid $100 million to secure option rights to an Ascentage drug. Elsewhere, J.P....